Related Experiment Video
Updated: Jul 29, 2025
06:09
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
8.8K
Melanoma: BRAFi Rechallenge
Christoforos S Kosmidis1,2, Konstantina Papadopoulou3, Chrysi Maria Mystakidou4
1European Interbalkan Medical Center, 10 Asklipiou Street, 55535 Pylaia, Greece.
Medicina (Kaunas, Lithuania)
|May 27, 2023
Summary
Targeted therapy, including BRAF inhibitors, is effective for advanced melanoma. Re-administering BRAF inhibitors can lead to significant survival benefits in patients with BRAF V600 mutation.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Melanoma is an aggressive skin cancer, with BRAF V600 mutations present in 50% of cases.
- Locally advanced melanoma poses significant treatment challenges, often requiring multimodal therapeutic strategies.
Observation:
- A case study of a 41-year-old patient with BRAF V600-positive locally advanced melanoma is presented.
- The patient received surgery, targeted therapy, immunotherapy, and subsequent re-administration of targeted therapy upon disease progression.
Findings:
- Re-administration of BRAF inhibitor therapy (BRAFi rechallenge) resulted in a significant overall survival exceeding four years.
- Preclinical models indicate that resistance mechanisms to BRAFi therapy can be overcome, allowing for effective re-treatment.
Implications:
- Targeted therapy, particularly BRAFi rechallenge, is a valuable strategy in managing advanced melanoma.
- Understanding resistance mechanisms is crucial for optimizing sequential treatment paradigms in melanoma management.
Related Concept Videos
01:30Skin Cancer
4.3K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.3K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Tumor Immunotherapy
577
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
577